Literature DB >> 12151714

O-acetyl sialic acid specific IgM in childhood acute lymphoblastic leukaemia.

S Pal1, M Chatterjee, D K Bhattacharya, S Bandhyopadhyay, C Mandal, C Mandal.   

Abstract

Initial studies have revealed an enhanced surface expression of O-acetylated sialoglycoconjugates (O-AcSGs) on lymphoblasts concomitant with high titres of IgG in childhood Acute Lymphoblastic Leukaemia (ALL) (Mandal C, Chatterjee M, Sinha D, Br J Haematol 110, 801-12, 2000). In our efforts to identify disease specific markers for ALL, we have affinity-purified IgM directed against O-AcSGs that reacts with three disease specific O-AcSGs present on membrane proteins derived from peripheral blood mononuclear cells (PBMC) of ALL patients. Antibody specificity towards O-AcSGs was confirmed by selective binding to erythrocytes bearing surface O-AcSGs, decreased binding with de-O-acetylated BSM and following pretreatment with O-acetyl esterase. Competitive inhibition ELISA demonstrated a higher avidity of IgM for O-AcSG than IgG. Flow cytometry demonstrated the diagnostic potential of purified O-AcSA IgM as binding was specific with ALL patients and minimal with other haematological disorders and normal individuals. It therefore may be adopted as a non-invasive approach for detection of childhood ALL. Taken together, the data indicates that carbohydrate epitopes having terminal O-AcSA alpha2 --> 6 GalNAc determinants induce disease specific IgG and IgM, potentially useful molecular markers for childhood ALL.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12151714     DOI: 10.1023/a:1019692329568

Source DB:  PubMed          Journal:  Glycoconj J        ISSN: 0282-0080            Impact factor:   2.916


  24 in total

1.  Identification of antibodies directed against O-acetylated sialic acids in visceral leishmaniasis: its diagnostic and prognostic role.

Authors:  M Chatterjee; V Sharma; C Mandal; S Sundar; S Sen
Journal:  Glycoconj J       Date:  1998-12       Impact factor: 2.916

2.  A novel method for prognostic evaluation of childhood acute lymphoblastic leukemia.

Authors:  D Sinha; C Mandal; D K Bhattacharya
Journal:  Leukemia       Date:  1999-02       Impact factor: 11.528

Review 3.  Investigation of 9-O-acetylated sialoglycoconjugates in childhood acute lymphoblastic leukaemia.

Authors:  C Mandal; M Chatterjee; D Sinha
Journal:  Br J Haematol       Date:  2000-09       Impact factor: 6.998

4.  Tandem application of flow cytometry and polymerase chain reaction for comprehensive detection of minimal residual disease in childhood acute lymphoblastic leukemia.

Authors:  G A Neale; E Coustan-Smith; Q Pan; X Chen; B Gruhn; P Stow; F G Behm; C H Pui; D Campana
Journal:  Leukemia       Date:  1999-08       Impact factor: 11.528

5.  Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia.

Authors:  J S Chen; E Coustan-Smith; T Suzuki; G A Neale; K Mihara; C H Pui; D Campana
Journal:  Blood       Date:  2001-04-01       Impact factor: 22.113

6.  Role of linkage specific 9-O-acetylated sialoglycoconjugates in activation of the alternate complement pathway in mammalian erythrocytes.

Authors:  V Sharma; M Chatterjee; G Sen; C A Kumar; C Mandal
Journal:  Glycoconj J       Date:  2000-12       Impact factor: 2.916

7.  Complement-mediated anti-HIV-1 effect induced by human IgM monoclonal antibody against ganglioside GM2.

Authors:  X Wu; N Okada; H Momota; R F Irie; H Okada
Journal:  J Immunol       Date:  1999-01-01       Impact factor: 5.422

8.  The specificity of the binding site of AchatininH, a sialic acid-binding lectin from Achatina fulica.

Authors:  G Sen; C Mandal
Journal:  Carbohydr Res       Date:  1995-03-01       Impact factor: 2.104

Review 9.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.

Authors:  N L Harris; E S Jaffe; H Stein; P M Banks; J K Chan; M L Cleary; G Delsol; C De Wolf-Peeters; B Falini; K C Gatter
Journal:  Blood       Date:  1994-09-01       Impact factor: 22.113

Review 10.  Sialic acids in molecular and cellular interactions.

Authors:  S Kelm; R Schauer
Journal:  Int Rev Cytol       Date:  1997
View more
  6 in total

1.  O-acetylation of sialic acids is required for the survival of lymphoblasts in childhood acute lymphoblastic leukemia (ALL).

Authors:  Shyamasree Ghosh; Suman Bandyopadhyay; Kankana Mukherjee; Asish Mallick; Santanu Pal; Chhabinath Mandal; Dilip K Bhattacharya; Chitra Mandal
Journal:  Glycoconj J       Date:  2007-01       Impact factor: 2.916

2.  Detection of disease specific sialoglycoconjugate specific antibodies in bronchoalveolar lavage fluid of non-small cell lung cancer patients.

Authors:  Sangeeta Mehta; Rakhee Chhetra; Radhika Srinivasan; Suresh C Sharma; Digambar Behera; Sujata Ghosh
Journal:  Glycoconj J       Date:  2010-05-16       Impact factor: 2.916

3.  9-O-acetylated sialic acids differentiating normal haematopoietic precursors from leukemic stem cells with high aldehyde dehydrogenase activity in children with acute lymphoblastic leukaemia.

Authors:  Suchandra Chowdhury; Sarmila Chandra; Chitra Mandal
Journal:  Glycoconj J       Date:  2014-10       Impact factor: 2.916

Review 4.  Functions and Biosynthesis of O-Acetylated Sialic Acids.

Authors:  Chitra Mandal; Reinhard Schwartz-Albiez; Reinhard Vlasak
Journal:  Top Curr Chem       Date:  2015

5.  The human Cas1 protein: a sialic acid-specific O-acetyltransferase?

Authors:  Sigrid Arming; Dirk Wipfler; Juliane Mayr; Anette Merling; Ulrike Vilas; Roland Schauer; Reinhard Schwartz-Albiez; Reinhard Vlasak
Journal:  Glycobiology       Date:  2010-10-14       Impact factor: 4.313

6.  Flow-cytometric monitoring of disease-associated expression of 9-O-acetylated sialoglycoproteins in combination with known CD antigens, as an index for MRD in children with acute lymphoblastic leukaemia: a two-year longitudinal follow-up study.

Authors:  Suchandra Chowdhury; Suman Bandyopadhyay; Chandan Mandal; Sarmila Chandra; Chitra Mandal
Journal:  BMC Cancer       Date:  2008-02-01       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.